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Abstract
Background: The number of studies describing the use of whole-body magnetic resonance imaging (WB-MRI) for
screening of malignant tumours in asymptomatic subjects is increasing. Our aim is to review the methodologies
used and the results of the published studies on per patient and per lesion analysis, and to provide
recommendations on the use of WB-MRI for cancer screening.
Main body: We identified 12 studies, encompassing 6214 WB-MRI examinations, which provided the rates of
abnormal findings and findings suspicious for cancer in asymptomatic subjects, from the general population. Eleven
of 12 studies provided imaging protocols that included T1- and T2-weighted sequences, while only five included
diffusion weighted imaging (DWI) of the whole body. Different categorical systems were used for the classification
and the management of abnormal findings.
Of 17,961 abnormal findings reported, 91% were benign, while 9% were oncologically relevant, requiring further
investigations, and 0.5% of lesions were suspicious for cancer.
A per-subject analysis showed that just 5% of subjects had no abnormal findings, while 95% had abnormal findings.
Findings requiring further investigation were reported in 30% of all subjects, though in only 1.8% cancer was
suspected. The overall rate of histologically confirmed cancer was 1.1%.
Conclusion: WB-MRI studies of cancer screening in the asymptomatic general population are too heterogeneous
to draw impactful conclusions regarding efficacy. A 5-point lesion scale based on the oncological relevance of
findings appears the most appropriate for risk-based management stratification. WB-MRI examinations should be
reported by experienced oncological radiologists versed on WB-MRI reading abnormalities and on onward referral
pathways.
Keywords: Whole-body imaging, Whole body screening, Magnetic resonance imaging, MRI, Incidental findings,
Cancer screening
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Background
Whole-body magnetic resonance imaging (WB-MRI) has
become established for the management of patients with
multiple epithelial and non-epithelial cancers, and
recently its use has been extended to early cancer detec-
tion in subjects with cancer predisposition syndromes [1,
2]. However, there is increasing interest in applying WB-
MRI to detect cancers in the general population given
the high sensitivity of the method that is free from ionis-
ing radiation. The premise being that earlier detection
and appropriate targeted interventions can modify the
risk of disease development and so promote precision
health. In this setting, imaging modalities can be com-
bined with other molecular diagnostics, such as genomic
profiling, biochemical tests and circulating cell-free
DNA. Highly sensitive molecular diagnostics can be used
to stratify each subjects’ risk of developing malignant
cancer. Thereafter, highly specific imaging tests such as
WB-MRI are used to detect and characterise abnormal-
ities in these subjects, allowing both early diagnosis of
malignant tumours for which interventions or surveil-
lance is warranted. This use of WB-MRI here is distinct
to its current role for promoting precision oncology
(Fig. 1). In this review, we first summarise the roles of
WB-MRI in oncology and cancer predisposition syn-
dromes, before examining the feasibility of using this
technique to more general population screening.
Guideline recommendations and key uses in known
cancers
The International Myeloma Working Group and the
British society of Haematology recommend the use of
WB-MRI for the detection and staging of multiple mye-
loma (Grade A recommendation, GR A) [3], as well as
for the detection of relapsed disease prompted by rising
serum paraprotein levels. Additionally, more regular use
of WB-MRI is recommended for the follow-up of oligo-
secretory/non-secretory disease and for patients with
extramedullary disease (Level of Evidence 1B, LE 1B) [4].
Guidelines have been published for the use of WB-MRI
in multiple myeloma (Myeloma Response Assessment
and Diagnosis System, MY-RADS) [5], including
standardized acquisition protocols, which rely on both
morphological and diffusion weighted imaging (DWI)
sequences..
In light of the good diagnostic performances for the
detection of metastases in several articles [6–8] the
German Dermatology Society, the Dermatologic
Cooperative Oncology Group and the updated Swiss
Guidelines suggested the use of WB-MRI as an alterna-
tive to 18-flurodeoxyglucose (FDG) PET/CT for the
staging of high-risk and metastatic (stage III or IV) mel-
anoma (LE 1A, GR B), and for the follow-up of stage IIC
or higher melanoma patients (LE 4) [9, 10].
WB-MRI is also being increasingly used for the man-
agement of patients where there is a propensity for
tumour spread to the bone marrow including prostate
and breast cancers [1]. The European Association of
Urology (EAU) recognized that WB-MRI is more sensi-
tive than choline PET/CT and bone scan for detecting
bone metastases in high-risk prostate cancer patients
[11], but acknowledges the limited availability of the
technique [12]. The Advanced Prostate Cancer Consen-
sus Conference (APCCC) noted that WB-MRI, although
less widely used, is more sensitive for detecting bone
metastases than conventional techniques such as com-
puted tomography and planar bone scans [13]. Recently,
an ASCO consensus guideline outlined a number of
clinical scenarios where next-generation imaging includ-
ing PET/CT, PET/MRI, or WB-MRI could have
Fig. 1 [Precision Health] vs [Precision Oncology] same technologies but different roles
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management impacts in men with advanced prostate
cancer [14]. Metastasis Reporting and Data System for
Prostate Cancer (MET-RADS-P) [15] guidelines pro-
vided a standardization of acquisition protocols, based
on morphological and DWI sequences, and a guidance
for image interpretation and structured reporting.
The application of WB-MRI in breast cancer (BC)
patients can be applied to two specific clinical subgroups
[16]. The first comprises BC patients with bone-
predominant or bone-only metastatic disease, where WB-
MRI is able to show progressive disease earlier than
computed tomography (CT) and bone scans, enabling
treatment changes at lower burdens of progressing disease
[17, 18]. The second comprises women who develop BC
during pregnancy. As a radiation-free imaging technique
requiring no contrast medium administration, WB-MRI
has been proposed as the technique of choice for systemic
staging of pregnant women developing BC [19, 20].
There is growing use of WB-MRI for the follow-up of
lymphoma patients with non-avid or variable FDG PET/
CT avidity where WB-MRI has superior diagnostic per-
formance to FDG-PET/CT [21]. Furthermore, WB-MRI
has a diagnostic performance comparable to FDG-PET/
CT in FDG avid lymphoma patients [22]. The enthusi-
asm for using WB-MRI as a surveillance method in chil-
dren and younger patients is motivated by the clinical
need to minimise radiation exposure following the
ALARA (As Low As Reasonably Achievable) principles
of radioprotection [23].
Finally, two large multicentre prospective studies have
been recently published, comparing the diagnostic ac-
curacy and efficiency of WB-MRI-based staging path-
ways with standard pathways in colorectal and lung
cancer [24, 25]. In both studies, WB-MRI staging path-
ways had similar accuracy to standard pathways and re-
duced staging time and costs.
Guideline recommendations in Cancer predisposition
syndromes
Several international guidelines recommend WB-MRI
for the early cancer detection in individuals with cancer
predisposition syndromes where regular surveillance is
necessary. These recommendations are underpinned by
the lack of ionizing radiation exposure using WB-MRI
and the good diagnostic performance for disease detec-
tion, with a sensitivity ranging from 50 to 90%, and a
specificity ranging from 93 to 95%, as described in the
largest studies available [24–26].
In the setting of Li-Fraumeni syndrome (LFS), guide-
lines developed by the National Comprehensive Cancer
Network (NCCN) and by the American Association for
Cancer Research (AACR) indicate annual WB-MRI
along with brain MRI with contrast (and breast MRI in
women) as the techniques of choice for the surveillance
of paediatric and adult subjects [27, 28]. Screening pro-
tocols that include WB-MRI for subjects with LFS have
been also proposed by Australian and Canadian re-
searchers [29, 30].
For children and adults with hereditary paraganglioma
and pheochromocytoma syndromes, the AACR also rec-
ommends biennial screening using WB-MRI [31].
In patients with neurofibromatosis, WB-MRI showed
good sensitivity in detecting the number, volume, and
distribution of neurofibromata in a study of 247 subjects
by Plotkin et al. [32]. In light of these results, the NCCN
recently suggested the development of practical guide-
lines to introduce WB-MRI for the detection of malig-
nant peripheral nerve sheath tumours and to establish a
standardized, cost-efficient WB-MRI protocol for image
acquisition [33].
In subjects with constitutional mismatch repair defi-
ciency syndrome (CMMRD), a consensus statement by
the Care for CMMRD Consortium and by the
International Biallelic Mismatch Repair Deficiency
Consortium recommends yearly WB-MRI from the age
of six [34] to screen for development of cancers.
Cancer screening in the general population
A meta-analysis [35] and systematic review [36] have re-
cently summarized the diagnostic yields of WB-MRI in
the population screening context, with particular focus
on the prevalence of relevant and indeterminate findings.
However, there are no evidence-based recommendations
on the key issues such as imaging protocols and strat-
egies for classifying and/or managing findings.
To address this short coming, we identified using
PubMed searches and cross-checking of citations, 14
studies published between 2005 and 2020 describing the
use of WB-MRI for cancer screening in asymptomatic
subjects in the general population. For 12 of the 14 stud-
ies (6423 subjects) the intended purpose was or included
cancer screening [37–48]. In the remaining two studies,
the main purpose was the mapping of body fat (148
subjects) [49], or cardiovascular disease screening (138
subjects) [50], with any lesion suspicious for cancer de-
scribed as incidental findings. These two studies were
not considered for this review. We note that the 209
subjects included in the pilot study by Perkins et al. [39]
were included also in the larger study by Hou et al. [40].
Therefore, this was considered in the overall count of
screened subjects, as reported in Table 1.
Imaging protocol
a) Literature review
In all 12 studies for cancer screening, the anatomical
coverage included head, neck, chest, abdomen and
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pelvis; however, the lower limbs were included in nine
studies (Supplementary Fig. 1). For all 12 studies it was
possible to obtain detailed information regarding the
orientation of the acquired images and the types of
sequences used in the WB-MRI protocol, which are
summarized in supplementary Table 1 and supplemen-
tary Fig. 1. In nine [39–41, 43–45, 47, 48], both T1 and
T2 weighted images were acquired across the whole
body, while in the remaining three studies, just one
morphological sequence was acquired (Table 1 and
supplementary Table 1). Whole body DWI sequences
were utilized in just five studies [39, 40, 42, 45, 47]. All
studies provided detailed information regarding the WB-
MRI protocol used for cancer screening. This illustration
provides a synthesis of the anatomical coverage and the
image orientation used for the standard unenhanced
examination, in the different body regions [Additional
Fig. 1]. Additional sub-protocols for the evaluation of
specific organs were performed in six studies.
Whole-body T1-weighted images were acquired in 11
studies [37–45, 47, 48], always using Gradient Echo
(GRE) sequences, while Turbo Spin-Echo (TSE) se-
quences were used only in one of them, in addition to
GRE. Whole-body T2-weighted images were acquired in
eight studies using TSE sequences: with fat-suppression
via Inversion Recovery techniques in five, with both fat-
suppressed and unsuppressed acquisitions in one, and
without fat suppression in two. Whole body DWI was
performed in five studies [39, 40, 42, 45, 47], always in
addition to the morphological T1 and/or T2-weighted
imaging.
Additional regional oncologic MRI sub-protocols were
performed in six out of 11 studies (Supplementary
Table 1), including comprehensive multi-sequence brain
MRI in four studies [37, 39, 40, 43], MR colonography in
two [37, 38], MRI mammography in one [43] and pros-
tate MRI in two [39, 40] (Supplementary Fig. 1). Six
studies made use of sub-protocols for the non-oncologic
evaluation of the cardiovascular system [37–40, 43, 45].
Supplementary Table 1 provides further details regard-
ing the protocols used in each study.
Intravenous contrast agent was administered in three
studies where WB-MRI was performed for cancer
screening. However, its use was motivated by additional
sub-protocols requiring contrast administration per-
formed in the same sitting, including cardiac MRI, MR
angiography and MR colonography [37, 38, 45]. In a
fourth study, contrast was administered in those patients
who accepted to undergo optional cardiac MRI, whole-
body MR angiography or MR mammography [43]. In
one study, intravenous contrast agent was administered
in a minority of subjects (12 out of 116) to further char-
acterise suspicious findings detected by the unenhanced
sequences [46].
b) Evidence Synthesis and recommendations
WB-MRI scanning protocols for cancer screening are
the analogous to protocols laid out for metastasis detec-
tion in advanced prostate cancer (MET-RADS-P) [15]
and multiple myeloma (MY-RADS) [5], with minor
modifications. Morphologic imaging forms the basis of
WB-MRI protocols in MET-RADS-P and MY-RADS
guidelines, with GRE T1-weighted images in axial or
coronal orientation considered mandatory from head to
mid-thigh for MET-RADS and to the knee for MY-
RADS, while axial TSE T2-weighted images without fat
suppression are considered optional. For cancer screen-
ing protocols, both T1-weighted and T2-weighted im-
ages without fat suppression are required for the optimal
localization and characterisation of findings. T1-
weighted imaging can be performed using a GRE Dixon
sequence, allowing fat-only, water-only and relative fat-
fraction images to be derived [51]. While T2-weighted
sequences with fat suppression have traditionally been
used in musculoskeletal studies, T2-weighted sequences
without fat suppression seem more suitable for onco-
logical studies and more time efficient, as recommended
by MET-RADS-P and MY-RADS guidelines, and are
therefore suggested for WB-MRI cancer screening..
Inclusion of the lower limbs is mandatory in WB-MRI
protocols for cancer screening in subjects with cancer
predisposition syndromes, such as Li-Fraumeni syn-
drome [30], due to high incidence of soft tissue cancers.
Since malignant lesions in the lower limbs have not been
reported in any studies of WB-MRI for cancer screening
in the general population, a protocol that covers from
head to mid-thigh is sufficient for cancer screening.
While the use of gadolinium-based contrast agents
can increase the diagnostic performance of WB-MRI in
some body regions (particularly the brain), it also repre-
sents a more invasive approach to imaging with unclear
benefits in asymptomatic subjects [52]. The largest
study included in our review (2500 subjects) highlights
the low diagnostic yield of contrast enhanced sub-
protocols, with only three tumours diagnosed by MRI
mammography and no tumours detected on post-
contrast T1-weighted imaging performed for whole-
body MRI angiography (WB-MRA) [43]. In fact, most
authors have avoided the use of contrast agent in gen-
eral cancer screening, except when cardiovascular risk
is also being assessed or when abnormalities are seen
during WB-MRI examinations requiring supplementary
contrast enhancement to arrive at a diagnosis. The is-
sues of gadolinium deposition in the brain and other
body tissues [53], and the discomfort related to intra-
venous puncture, represent further disincentives for its
use in general cancer screening, therefore the use of
contrast agents is not recommended.
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Diffusion sequences have shown high sensitivity for
cancer detection across multiple body regions; however,
only seven studies included in our review made use of
this technique. Outside the brain, DWI sequences were
limited to the upper abdomen in two studies and used
for whole-body evaluation in five studies [39, 40, 42, 45,
47]. Notably, the studies including DWI were published
after year 2009, whereas three out of five studies not
using DWI were published before 2009. It is interesting
to note that recognition of the usefulness of DWI for
cancer imaging emerged from a consensus conference of
the International Society for Magnetic Resonance in
Medicine [54] published in 2009. Progress in MRI tech-
nology has both improved DWI image quality and re-
duced acquisition times, making this technique highly
suitable for whole-body imaging. Therefore, DWI should
be used, pending future studies investigating WB-MRI
with DWI for general cancer screening.
With existing commercial MR hardware and se-
quences, the proposed mandatory components could be
acquired in under thirty minutes (Table 2). Additional
regional assessments with specific sequences, for ex-
ample brain examinations with FLAIR sequences and
lungs evaluation with short echo-time GRE. Additional
T1 weighted, and T2 weighted images with fat suppres-
sion of the spine, are recommended for metastasis detec-
tion by MET-RADS-P and MY-RADS guidelines, but
this may not be necessary in the setting of cancer
screening; in fact, only four screening studies include sa-
gittal imaging of the spine.
To avoid errors and reduce the demands on radiogra-
phers, we strongly recommend the composing of con-
tiguous imaging blocks for each sequence, as well as the
automated calculation of derived images (e.g. water, fat
and fat fraction from Dixon images, and reconstruction
of maximum intensity projections of the high b-value
DWI images), when possible.
Reading and reporting
In a study on the diagnostic performance of WB-MRI
for cancer screening in subjects with LFS, Anupindi
et al. proposed that the examinations must be reported
by radiologists with experience in oncologic WB-MRI
[55]. We suggest extending this recommendation to
WB-MRI for cancer screening also, where it is extremely
important that readers are experienced enough to avoid
harms through unnecessary additional testing on the
one hand, and to have detailed knowledge of common
cancer guidelines and of best practice recommendations,
to appropriately advise subjects with relevant findings.
To date, the number of WB-MRI examinations a radi-
ologist should report to gain enough expertise is not
known, as no study has formally addressed this issue.
However, it is likely that the required expertise can be
most readily be reached by oncological radiologists, who
routinely report WB-MRI examinations in cancer pa-
tients. Where this may not be possible or practical,
Greer et al. have suggested that centres with a low
volume of WB-MRI examinations could benefit from
central review of such examinations by more experi-
enced readers [56].
Strategies for the classification of WB-MRI findings
a) Literature review
Seven studies reported the use of categorical systems
for the classification of findings. Two studies made use
of a binary classification distinguishing between non-
relevant (benign and not requiring further evaluation) or
relevant findings (requiring further imaging or diagnostic
workup) [37, 41]. Three studies classified findings into
three categories, as either non-relevant (benign, not sig-
nificant), relevant (requiring further evaluation) or highly
relevant (malignant, highly significant) [44, 45, 48]. One
Table 2 proposed WB-MRI protocol for cancer screening in asymptomatic subjects of the general population
Sequence description Characteristics Recommendation
1 Whole-body (head to mid-thigh) T1W GRE, Dixon technique Axial or coronal (5 mm slice thickness) Mandatory
2 Whole-body (head to mid-thigh) T2W, TSE without fat- suppression Axial or coronal (5 mm slice thickness) Mandatory
3 Whole-body (head to mid-thigh) DWI, STIR fat suppression,
contiguous slicing, multiple stations
• ADC calculations with mono-exponential data fitting
• 3D-MIP reconstructions of highest b-value images*
Axial (5 mm slice thickness)
2 b-values:
• b50–100 s/mm2
• b800–1000 s/mm2)
Mandatory
Additional regional assessments:
4 • Brain: T2W FLAIR Brain: Axial (5 mm slice thickness) Optional
5 • Lung: T1 GRE short echo-time single breath hold Lung: Axial (< 3 mm slice thickness) Optional
6 • Whole spine T1W, TSE Sagittal (4–5 mm slice thickness) Optional
7 • Whole spine STIR (preferred) or fat suppressed T2W Sagittal (4–5 mm slice thickness) Optional
W=weighted; TSE = turbo spin echo; STIR = short tau inversion recovery; GRE = gradient echo; DWI = diffusion weighted imaging; ADC = apparent diffusion
coefficient; MIP =maximum intensity projection; FLAIR = FLuid Attenuated Inversion Recovery
* Whole-body rotational 3D MIP images rotating along the cranio-caudal axis (≤3 degrees of rotation per frame), displayed using an inverted grey scale
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study classified findings into four categories (non-rele-
vant, relevant benign, relevant unclear, relevant malig-
nant) [43], while the remaining study used five
categories (definitely benign, likely to be benign, equivo-
cal, likely to be malignant, definitely malignant) [47].
Findings related to cardiovascular diseases were reported
in a separate section for the six studies that included
cardiac or angiographic imaging sub-protocols, but these
are not relevant to the current discussion, which is fo-
cused on oncologic findings.
b) Evidence synthesis and recommendations
Strategies adopted for classification of findings differed
widely, rendering systematic comparison between stud-
ies difficult. For example, the binary classifications
adopted in two studies [37, 41] does not describe the
number of subjects with a strong suspicion for tumour,
therefore reducing the interpretability of the results.
Similarly, in one study [44] where three categories were
used, the rate of highly relevant findings (0.4%) also in-
cluded non-neoplastic findings requiring immediate re-
ferral, implying that the rate of oncologically relevant
findings was lower. This difference may not be clear to
subjects willing to undergo the examination, creating er-
roneous expectations regarding the performance of WB-
MRI for cancer screening in the general population.
The adoption of a standardized structured report akin
to disease specific MET-RADS-P and MY-RADS tem-
plates adapted for screening applications will likely im-
prove reporting repeatability, as well as provide greater
reproducibility and comparability across studies. Such a
reporting template has yet to emerge for general popula-
tion screening. We believe that a classification system
based on five categories should be adopted at a lesion
level to indicate the likelihood of malignancy in cancer
screening setting. Category 1 and 2 for normal and be-
nign findings, and categories 3, 4 and 5 for findings with
increasing oncological relevance (Table 3). Stratification
of the oncological relevance of findings would allow the
application of different strategies for investigations and
patient management.
Strategies for the management of WB-MRI findings
a) Literature review
The management of relevant findings was only de-
scribed in five studies, representing less than half of the
reviewed papers. In three, detailed descriptions of the
management of relevant findings was reported: Lo et al.
[41] made use of additional imaging evaluations for spe-
cific body regions (ultrasound for thyroid nodules, CT
for lung nodules, pancreatic and retroperitoneal lesions,
contrast enhanced MRI for liver, kidney and prostate le-
sions, plain radiograph for long bones focal lesions);
Ulus et al. [46] performed dedicated contrast enhanced
MRI studies in the same sitting of WB-MRI for the ma-
jority of suspicious findings and used CT for lung nod-
ules; Goehde et al. [37] made use of region specific
imaging modalities (CT scans for lung nodules, MRI for
brain, liver, kidney and bone lesions, sonography for thy-
roid nodules) and direct histopathological verification
for clearly malignant masses (kidney). In the remaining
two studies [43, 47], further management was discussed
by a multidisciplinary board, but provided no descrip-
tions of additional examinations undertaken.
b) Evidence synthesis and recommendations
The adoption of a standardised management of rele-
vant findings represents a critical gap for the general use
of WB-MRI for cancer screening. Given the high sensi-
tivity of the technique, successful adoption of WB-MRI
depends on having the means and methods to manage
the entire range of findings generated by a single WB-
MRI examination. Management should follow estab-
lished guidelines for incidental findings in the different
body regions as far as possible, such as those for lung
nodules [57], renal cysts [58], pancreatic cysts [59] and
the Radiology White Papers for Managing Incidental
Findings on Abdominal and Pelvic CT and MRI [60],
also requiring the establishment of specific onward refer-
ral pathways for all findings observed.
Abnormal findings in WB-MRI: per-finding and per-subject
analysis
A per-finding analysis of the outcome of WB-MRI was
possible in six studies (Table 1), which reported a total
of 17,961 findings. From a per-finding perspective, 91%
of reported findings were non-relevant and 9% were
oncologically relevant (i.e. requiring further investiga-
tion). In the four studies that also provided the rate of
highly relevant findings (i.e. suspicious for malignancy),
this proportion reached 0.5% of all findings. The number
of findings suspicious for malignancy reported in each
study across the different body regions are summarized
Table 3 proposed classification system for findings detected by
WB-MRI
Category Likelihood of cancer
1 Normal
2 Benign
3 Equivocal
4 Suspicious
5 Very suspicious
1–2 = no follow-up
3–4-5 = follow-up or further investigation triggered by WB-MRI
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in Table 4. Notably, no suspicious tumours were re-
ported in the lower limbs in the general population, des-
pite coverage across 4800 examinations.
A per-subject analysis of the outcome of the WB-MRI
was possible in five studies (Table 1). From a per-subject
perspective, 94% of the WB-MRI examinations were re-
ported to show some abnormal findings while 6% were
entirely normal. Nearly 30% of all WB-MRI yielded
oncologically relevant findings, while highly relevant
findings arose in only 1.8% of people. Despite the high
number of findings detected by WB-MRI, the rate of ex-
aminations that potentially lead to further diagnostic
evaluations, such as further imaging studies, remains
relatively low, around 30%. This highlights the ability of
WB-MRI not only for lesion detection but also for the
characterization of potential abnormalities.
Cancer detection
a) Literature review
On a per-subject basis, across eleven studies [37–39,
41–48], a total of 93 WB-MRI examinations out of 5233
were reported as positive for malignancy (1.8%). Notably
however, in the 10 studies [37–42, 44, 46–48] that re-
ported the number of confirmed malignant cancers,
these were ultimately established in 41 out of 3692 ex-
aminations (1.1%) (Table 1).
a) Evidence synthesis
The cancer detection rate of WB-MRI in the general
population is comparable to those observed in other
cancer screenings. In a meta-analysis by Blanks et al.
[61] showed a detection rate of 7.59 per 1000 subjects
(0.8%) for breast cancer at prevalent screening with
digital mammography. Notably, a meta-analysis by Bal-
linger et al. [62] conducted in subjects with Li-Fraumeni
Syndrome undergoing surveillance with WB-MRI re-
ported a much higher cancer detection rate of 7%.
Therefore, WB-MRI for screening in the general popula-
tion should be assessed keeping in mind that the likely
low prevalence of malignant tumours in these subjects
will influence the negative predictive value (NPV) of the
examination. On the other hand, the presence of risk
factors and relevant family history for cancer should be
carefully collected, to allow personalised stratification of
the subjects’ cancer risk.
By the same measure, before WB-MRI examination,
subjects from the general population should be informed
about both the low pre-test probability of detecting ma-
lignant cancer and the high likelihood of findings requir-
ing follow-up investigations. The NPV for the presence
of a malignant tumour will depend upon the sensitivity
of WB-MRI and from the prevalence of such disease in
the population being evaluated. A meta-analysis by Li
et al., including 1067 patients with different tumour
types from 13 studies, calculated a pooled per-patient
sensitivity and specificity for the detection of primary
and/or metastatic lesions by WB-MRI with DWI of 90
and 95%, respectively [26]: from these results we calcu-
lated a NPV of 96%. Considering the lower prevalence of
malignant tumours (reported average < 2%) in asymp-
tomatic subjects of the general population undergoing
WB-MRI for cancer screening, as a consequence we
would expect even higher NPV values for WB-MRI in
cancer screening, also emphasising the need to adjust
the threshold for prompting further investigations of in-
cidental findings. Therefore, given the low probability of
diagnosing malignant cancer, a high threshold should be
applied when requiring additional diagnostic tests for
abnormal findings in the general population, to avoid
over-investigations. In-depth investigations should be
considered only for definite abnormalities, for which on-
ward diagnostic pathways should be planned according
to existing guidelines and good practises.
Patient acceptability
Given the high frequency of “abnormal” findings at WB-
MRI screening, importance should be given to the pos-
sible repercussions on quality of life and patient anxiety.
In 2013, Schmidt et al. published the results of a survey
conducted on 471 subjects from the SHIP study, who
had been notified of the presence of potentially relevant
findings [63]. Among these subjects, 10% reported
strong distress while awaiting for WB-MRI results (six
weeks) and 29% reported moderate to severe distress
after receiving the results. The same authors examined
the long-term impact on quality of life and depressive
symptoms [64] by surveying 2188 subjects 2.5 years after
WB-MRI and 2232 individuals who had not undergone
WB-MRI. The survey did not detect significant differ-
ences in quality of life and depressive symptoms between
the two groups, or between the subjects who had been
notified with potentially relevant findings and those who
had not. The authors concluded that, while WB-MRI
can generate distress and anxiety in the short term, it is
generally well accepted in the long term, with quality of
life and subjective stress-levels comparable to those of
other already existing cancer screening programs.
Conclusions
Despite the heterogeneous methodology and the variable
results of WB-MRI studies performed for cancer screen-
ing in the general population, we can make a few gener-
alised conclusions:
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 The typical imaging protocol comprises T1-
weighted GRE, T2-weighted FSE (fast spin-echo)
and diffusion weighted sequences, extending from
the head to mid-thigh, with optional additional re-
gional assessments. The administration of intraven-
ous contrast agent is not recommended.
 Abnormal findings are expected in about 95% of
screened subjects, about 30% of subjects would
require further investigations but less than 2% would
be reported as suspicious for malignant cancers.
 Findings should be classified using a categorical
system, based on their likelihood of malignancy. It is
important to set high thresholds for further
investigations to minimize harms from diagnostic
testing.
 Subject counselling on the high likelihood of
incidental findings and the low likelihood of cancer
detection together with established onward referral
pathways are needed.
 Training is needed for reporting WB-MRI examina-
tions; however, the number of examinations a radi-
ologist should report to acquire this expertise still
has to be investigated.
Guidelines are needed to establish common strategies
for the classification and management of abnormal find-
ings in studies using WB-MRI for cancer screening. The
current experience is still too heterogeneous to draw
meaningful conclusions regarding general efficacy. Fu-
ture multisite studies should aim to provide the evidence
that may pave the way to guidelines and recommenda-
tions for asymptomatic population screening.
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